The Impact of Clinical Risk
By Fintan Walton
Pharma Deals Review: Vol 2006 Issue 70 (Table of Contents)
Published: 1 Apr-2006
DOI: 10.3833/pdr.v2006.i70.539 ISSN: 1756-7874
Section: Business Commentaries
Fulltext:
Abstract
Most risk is linked to research into and the development of new drug entities; about 80% of all drugs fail clinical trials because of either toxicity or efficacy issues. Closely associated with these problems are the increasing costs of clinical trials, which will make it more difficult for biotech companies to take products through to clinical proof-of-concept in Phase II. What is the solution?
Copyright: © IQVIA 2018